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Herpes simplex virus encodes proteins, such as DNA polymerase, that are essential for its replication and proteins, such 
as thymidine kinase, that are not essential for replication in cell culture, but are important for pathogenesis in animal models. 
However, certain mutations affecting these proteins exert little or no effect on replication or pathogenesis. We tested the 
effects of combining two such mutations -- one that alters DNA polymerase and one that decreases but does not abolish 
thymidine kinase activity--on replication in cultured cells and on acute and latent infections in mice. The double mutant 
replicated similarly to the single mutants and wild-type virus both in cell culture and acutely in the mouse eye. However, it 
was severely impaired for acute replication in trigeminal ganglia and for reactivatable latent infections. This impairment 
depended upon the polymerase mutation. Similarly, although Ro 31-5140, a thymidine kinase inhibitor, did not potentiate 
the antiviral effects of phosphonoacetic acid, a polymerase inhibitor, in cell culture, the two drugs in combination substantially 
inhibited viral reactivation from latency at concentrations that had little or no effect when used singly. These synergistic 
effects may have implications for viral functions during pathogenesis and for antiviral chemotherapy. © 1995 Academic 
Press, Inc. 
INTRODUCTION 
Infections of mammalian hosts by herpes simplex virus 
(HSV) proceed via replication at the periphery, followed 
by access to nerve terminal, acute replication in ganglia, 
and establishment of latency. Latent infection of humans 
serves as a life-long reservoir of virus that can reactivate, 
leading to recrudescent disease. 
The roles of specific viral gene products in these pro- 
cesses are of considerable interest, both in terms of 
basic biology and in terms of treating human disease. 
Among its >70 gene products, HSV encodes numerous 
proteins that are involved in the replication of its DNA 
(reviewed in Challberg and Kelly, 1989). Seven of these, 
including the viral DNA polymerase, directly participate 
in DNA replication and are essential for viral growth in 
cell culture. In part because it is essential, the HSV DNA 
polymerase serves as an excellent target for inhibition 
by antiviral drugs such as acyclovir (reviewed in Coen, 
1992). Other DNA replication proteins, such as thymidine 
kinase (TK), participate less directly and are not essential 
in cell culture. This latter class of proteins can be very 
important, however, in viral pathogenesis. In particular, 
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HSV mutants that completely lack TK activity are unable 
to replicate acutely within or reactivate from latent infec- 
tion of mouse ganglia due to the tk mutation (Coen et 
al., 1989b; Efstathiou et aL, 1989; Jacobsen eta/., 1993). 
These kinds of results have led to efforts to develop 
inhibitors of TK as antiviral drugs (Spadari and Wright, 
1989; Wright, 1994). Additionally, TK is required for the 
efficient activation of antiviral nucleoside analogs such 
as acyclovir to their phosphorylated forms; thus, TK-nega- 
tive mutants are resistant to acyclovir (Coen, 1992). 
Despite the important roles of the viral DNA polymer- 
ase and TK in replication and pathogenesis, there are 
many relatively subtle mutations that can affect either of 
these functions with little or no effect on replication or 
pathogenesis. Many of these confer resistance to antivi- 
ral drugs such as acyclovir (Larder and Darby, 1984). For 
example, although the viral polymerase is essential in 
cell culture, there are numerous drug resistance pol mu- 
tations that permit efficient viral replication and substan- 
tial pathogenicity (Larder and Darby, 1984; Field and 
Coen, 1986). Similarly, we have previously shown that a 
mutation that decreases TK levels at least 10-fold has 
no effect on latency in a mouse model (Coen et al., 
1989a). These findings not only have implications for 
acyclovir resistance in clinical settings, but raise ques- 
tions regarding the evolutionary significance of particular 
properties of HSV-encoded enzymes such as high levels 
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To address some of these issues, we investigated the 
behavior of a mutant, PKG7, that contains two relatively 
subtle mutations, one in pol and one in tk. These two 
mutations appear to impair HSV pathogenicity in a syner- 
gistic manner. This behavior led us to test whether drugs 
that inhibit DNA polymerase and TK could also be syner- 
gistic. 
MATERIALS AND METHODS 
Cells and viruses 
African green monkey kidney cells (Vero) were propa- 
gated as described (Weller eta/., 1983). Viruses used in 
this study were wild-type HSV-1 strain KOS, PAAr5 (Jofre 
eta/., 1977; Coen eta/., 1983; Gibbs eta/., 1988), KG111 
(Coen eta/., 1980; Irmiere eta/., 1989), PKG7 (Irmiere et 
a/., 1989), and PKG7R (this report). Viruses were propa- 
gated and titered as described (Coen eta/., 1985). 
Marker rescue 
Marker rescue was performed as described (Chiou et 
aL, 1985) using PKG7 infectious DNA and a 1.7-kb Kpnl 
fragment (kindly provided by C. Hwang) from the wild- 
type KOS pol gene corresponding to the region where 
the PAA% mutation maps (Gibbs eta/., 1985). 
DNA sequencing 
Direct sequencing of polymerase chain reaction (PCR) 
amplified DNA was performed by the method of Gyllens- 
ten and Erlich (1988). Briefly, 1190-and 388-bp fragments 
including the 3' ends of both the pc~ and UL31 genes 
were amplified (30 cycles) from PKG7 DNA using primer 
pairs CGCGCTGTTTCTGCCCCCCA and CATGCTGTA- 
CGTCATCTTTCC and GGCGTGCGTGACATTCAAGG 
and ACCGGCTCATAGACCGGATG, respectively. Ali- 
quots of these PCR products (sometimes following gel 
purification) were then subjected to a second round of 
amplification (60 cycles) using 50 pmol of one primer 
and 5 pmol of the other. The resulting single-stranded 
PCR products were then purified on Centricon 100 col- 
umns and sequenced with primers AGAGGGACATCC- 
AGGACTTTG, GGAGGAAACTCGTCGAATG-FI-, and the 
amplification primers using Sequenase and Taqence 
from USB. 
Single cycle growth assays 
Vero cells (2 X 106 ) were seeded in 15-ml tissue cul- 
ture tubes in 1 ml of DME plus 5% newborn calf serum. 
One day later, a sample tube was trypsinized and the 
cells counted. The remaining tubes were infected at an 
m.o.i, of 3, as previously described (Schaffer eta/., 1978). 
After 1 hr the inocula were removed and the cells were 
washed three times with PBS and overlaid with 2 ml 
DME containing 5% newborn calf serum. After 20 hr at 
37 °, infected cells were frozen, thawed, sonicated, and 
centrifuged. The supernatants were titered, and burst 
size was calculated by dividing the total virus in the su- 
pernatant by the number of cells infected. 
Plaque size measurements 
Crystal violet-stained plaques were measured at their 
widest points using dental calipers after a standard 
plaque assay (Coen eta/., 1985), At least 30 plaques 
were measured for each virus and the mean plaque size 
was calculated. 
Assays of acute and latent infections in mice 
Assays using the mouse corneal model of acute and 
latent infection were performed as described (Leib eta/., 
1989, 1991; Jacobson et aL, 1993). Briefly, acute replica- 
tion in the mouse eye was assayed by determining the 
peak titers found in eyeswabs during the first 4 days 
postinoculation. Acute ganglionic replication was as- 
sayed by titering homogenates of trigeminal ganglia 3 
days postinoculation. Reactivation from latent infection 
was assayed either by cocultivation of ganglionic slices 
with Vero cells (Leib et aL, 1989) or by dissociation of 
ganglia into individual cells, followed by plating those 
cells onto Vero cell monolayers (Leib et aL, 1991 Jacob- 
son et aL, 1993). 
Drug assays 
Ro 31-5140 was kindly provided by J. A. Martin (Roche 
Research Centre, Welwyn Garden City, UK). Phospho- 
noacetic acid (PAA) was purchased from Sigma. Plaque 
reduction assays were performed as described (Coen et 
al., 1985). To test the effects of the inhibitors on reactiva- 
tion, the dissociation assay (Leib et aL, 1991; Jacobson 
et aL, 1993) was used with the concentration(s) of drug(s) 
ind]cated throughout he dissociation procedure. 
RESULTS 
A mutant containing relatively subtle pol and tk 
mutations is severely impaired for ganglionic 
replication and reactivation 
We initiated these studies to test the effects of rela- 
tively subtle mutations in DNA replication genes on HSV 
pathogenesis and latency in a mouse model. We pre- 
viously reported on an HSV mutant, KG111, which speci- 
fies low levels of truncated, but active TK (Irmiere eta/., 
1989; Coen et al., 1989a). This mutant is not detectably 
affected in its ability to replicate acutely in or reactivate 
from murine trigeminal ganglia following corneal inocula- 
tion (Coen et aL, 1989a). A second, relatively subtle muta- 
tion is that of PAAr5. This virus contains a point mutation 
in its pol gene that confers resistance to certain antiviral 
drugs and hypersensitivity to others (Gibbs et al., 1988). 
PAAr5 replicates efficiently at the periphery following in- 
oculation in the mouse ear, but is attenuated for neurovi- 
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TABLE 1 
VIRAL REPLICATION AND PLAQdE SIZE IN VERO CELLS 
Burst size Mean plaque 
Virus (% of KOS) ~ size (mm) 
KOS 128 (100) 1.7 
KG111 96 (75) 1.7 
PAA% 72 (56) 1.6 
PKG7 133 (104) 1.5 
PKGTR 119 (93) 1.6 
a Results shown are the average of two to four samples. 
rulence following intracerebral inoculation (Field and 
0oen, 1986). A third mutant, PKG7, was constructed by 
marker transfer of the KG111 tk gene into PAAr5 and thus 
is a double mutant (Irmiere et aL, 1989). 
We first compared the replication of PKG7, PAAr5, and 
I(Glll with their wild-type parent, strain KOS, in Vero 
cells. The plaque sizes and yields in single cycle growth 
experiments are shown in Table 1. Although the plaque 
sizes were similar, when these data were subjected to 
a statistical analysis (Student's t test), the mean plaque 
size of PKG7 was significantly smaller than those of KOS 
and KG111 (P < 0.01), but not that of PAA%. On the other 
hand, the yield of PKG7 was higher than those of KOS, 
KG111, and PAAr5. We conclude that PKG7, PAArS, and 
KG111 replicated in cell culture similarly to their wild- 
type parent, KOS. 
We then compared the behavior of the four viruses 
following corneal inoculation of mice (Table 2). With the 
possible exception of PAAr5, there was little or no differ- 
ence in the ability of the four viruses to replicate in the 
mouse eye. However, while KOS, KG111, and PAAr5 repli- 
cated comparably in the ganglia, there was no detectable 
ganglionic replication in mice infected with PKG7. Simi- 
larly, KOS, KG111, and PAA% reactivated from latent in- 
fections fairly efficiently; however, no reactivation was 
observed in ganglia of mice infected with PKG7. Thus, 
unlike the single mutants, KG111 and PAA~5, PKG7 was 
severely impaired for ganglionic replication and reacti- 
ratable latent infections. (We use the terminology, "reacti- 
vatable latent infections" to indicate that the impairment 
could be due to a failure to establish latency, to reacti- 
vate, or both.) PKG7 was also more attenuated for neuro- 
virulence following intracerebral inoculation than was 
KG111 or PARr5 (E. Pelosi and D. M. Coen, unpublished 
results). 
A pol mutation is essential for the impairment of 
PKG7 
To determine whether the PKG7 phenotype in mice 
required a pol mutation, we performed marker rescue. 
The PAAr5 pol mutation confers aphidicolin hypersensi- 
tivity, permitting selection of rescued progeny (Coen et 
aL, 1983). Cotransfection of PKG7 with the 1.1-kbp Kpnl 
fragment from KOS that rescues the PAAr5 mutation 
(Coen et aL, 1983; Gibbs et al., 1985) increased the per- 
centage of progeny that could form plaques in 0.5 #g/ 
ml aphidicolin by more than 100-fold compared to the 
progeny of transfected PKG7 DNA alone (data not 
shown). A plaque was isolated in the presence of aphidi- 
colin and subjected to two more rounds of plaque purifi- 
cation. The resultant virus was named PKG7R. PKG7R 
was no longer resistant to PAA, confirming that the pol 
mutation had been rescued, but retained resistance to 
bromovinyldeoxyuridine, confirming that the tk mutation 
was retained (data not shown). 
The 1.1-kbp Kpnl fragment contains not only a portion 
of the pol gene, but also encodes the very C-terminus of 
the UL31 gene, the 3' untranslated region of UL31 mRNA 
and the putative UL31 polyadenylation signal (McGeoch 
eta/., 1988). To determine if PKG7 contains any mutations 
that could affect UL31, we sequenced PKG7 DNA from 
the Kpnl site within the UL31 gene to 75 bases down- 
stream of the putative UL31 polyadenylation signal. The 
sequence was identical to that of wild-type strain KOS 
(Gibbs et aL, 1985). 
We then compared the behavior of PKG7R to that of 
PKG7 and KOS in mice. PKG7R was able to replicate in 
ganglia and reactivate from latency, similar to KOS (Table 
3). We conclude that a pol mutation is required for the 
impairment of PKG7. 
Synergistic inhibition of reactivation from latency 
The phenotype of PKG7 for ganglionic infections of 
mice was much more severe than PAAr5, KG111, or 
PKG7R alone, and more severe even than when the ef- 
fects of the PAAr5 and KG111 mutations were added or 
multiplied together. This suggested that the KG111 tk 
mutation and the PARr5 poI mutation act synergistically 
TABLE 2 
ACUTE AND LATENT INFECTIONS OF MICE 
Acute eyeswab Acute ganglia Reactivation 
Virus titers a titers ~ (%)° 
KOS 3.9 + 0.8 2.6 -4- 1.6 16/16 (100) 
KG111 3.9 4- 0.7 3.1 + 0.9 18/23 (78) 
PARr5 2.5 4- 0.9 2.5 4- 1.8 13/22 (59) 
PKG7 4.1 4- 0.8 <0.7 0/12 (0) 
a Logic mean of peak eyeswab titers from four mice + standard 
deviation. 
b Logm mean of ganglionic titers 3 days postineculation from four 
ganglia + standard eviation. 
c Reactivation is expressed as the number of ganglia harvested 30 
days postinoculation reactivating/the number of ganglia assayed. The 
percentage of ganglia reactivating is shown in parentheses. Reactiva- 
tion was measured by dissociation, and the results shown are the 
pooled results of several experiments. 
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TABLE 3 
EFFECT OF poI MUTATION IN PKG7 ON ACUTE AND LATENT INFECTIONS 
Acute eyeswab Acute ganglia Reactivation 
Virus titers a titers b (%)° 
KOS 4.9 +_ 0.4 4.3 + 0.5 5/6 (83) 
PKG7 2.7 -+ 1.6 <0.7 0/8 (0) 
PKG7R 4.9 +- 0.2 3.6 4- 0.8 6/8 (75) 
Log~0 mean of peak eyeswab titers from four mice _+ standard 
deviation. 
b Log10 mean of titers 3 days p0stinoculation from four ganglia _+ 
standard deviation. 
° Reactivation is expressed as the number of ganglia reactivating 
harvested 30 days postinoculation/the number of ganglia assayed. The 
percentage of ganglia reactivating is shown in parentheses. Reactiva- 
tion was measured by cocultivation. 
to prevent replication in the ganglia and reactivatable 
latent infection. This in turn led to the hypothesis that 
inhibitors of thymidine kinase and DNA polymerase 
might synergize for inhibition of reactivation from trigemi- 
nal ganglia. To test this hypothesis, we used the thymi- 
dine kinase inhibitor, Ro 31-5140, and the DNA polymer- 
ase inhibitor, PAA. Either 100 #M Ro 31-5140 or 300 
#g/ml PAA can inhibit reactivation of HSV from mouse 
trigeminal ganglia nearly completely (Jacobson et aL, 
1993 and unpublished results), but at lower concentra- 
tions they are less effective. To test for synergy, we disso- 
ciated ganglia from mice infected with HSV strain KOS 
onto monolayers of susceptible Vero cells and incubated 
these either with each drug alone at a concentration 
fourfold lower than its effective concentration or with both 
drugs at the same concentrations. The results are sum- 
marized in Table 4 in terms of fractions of cultures show- 
ing HSV cytopathic effect after 8 days in culture. Each 
drug alone at this concentration had little or no effect in 
this assay, While in combination, reactivation was inhib- 
ited >90%. Thus, at these concentrations, the combina- 
tion was much more effective than either drug alone 
or even when the effects of each drug were added or 
multiplied together, i.e., the combination was synergistic. 
TABLE 4 
EFFECTS OF PAA, RO 31-5140, OR BOTH ON REACTIVATION 
OF WILD-TYPE VIRUS 
Drug added Reactivation (%)a 
None 11/12 (92) 
75 #g/ml PAA 13/16 (81) 
25 #M Re 31-5140 13/15 (87) 
75 #g/ml PAA + 25/~M Re 31-5140 1/14 (7) 
a Reactivation was performed by a dissociation assay (Leib et aL, 
1991 ; Jacobsen et aL, 1993). Cultures were assayed as virus positive 
or negative by cytopathic effect 8 days after dissociation and plating 
onto a Vero cell monolayer. 
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FIG. 1. Lack of effect of Re 31-5140 on antiviral activity of PAA. Plaque 
reduction assays were performed in Vero cells on strain KOS at the 
indicated concentrations of PAA in the absence of Ro 31-5140 (e), in 
the presence of 20/~M Ro 31-5140 (El), or 100 #M Ro 31-6140 (A). 
We then tested whether this synergism was specific 
for reactivation or could be due merely to Ro 31-5140 
potentiating the antiviral activity of PAA in Vero cells, 
which were used to detect reactivation. We performed 
plaque reduction assays in Vero cells of different doses 
of PAA either in the absence of Ro 31-5140 or in the 
presence of 20 or 100 #M Ro 31-5140 [which by itself 
does not have antiviral activity in Vero cells at these 
concentrations (Jacobson et aL, 1993)]. Neither concen- 
tration of Ro 31-5140 potentiated the antiviral activity of 
PAA (Fig. 1). Thus, the combination is specifically syner- 
gistic for reactivation from nervous tissue. 
DISCUSSION 
Mechanism of synergistic inhibition 
PKG7 is much more attenuated for ganglionic replica- 
tion and reactivatable latent infection than are KG111 
and PAAr5 and this attenuation is dependent on the pres- 
ence of the pc~ mutation. The simplest interpretation of 
the results is that the pc~ mutation acts synergistically 
with the tk mutation to impair ganglionic replication and 
reactivatable latent infection. These results do not pre- 
clude the more complicated possibility, however, that the 
pc~ mutation acts synergistically with an unknown third 
mutation in PKG7. Additionally, in the absence of assays 
to detect latent genomes and their biological activity, we 
cannot say for certain whether the impairment of PKG7 
for reactivatable latent infection is due to a defect in 
establishment of latency, reactivation, or both. Because 
it mimics mutants that completely lack TK activity in its 
robust replication at the cornea and failure to replicate 
acutely in ganglia, we speculate that the chief defect is in 
reactivation with less profound defects in establishment 
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(Ooen et al., 1989b; Jacobson et al., 1993). The results 
with PAA and Ro 31-5140 argue that subtle po l  and tk 
mutations by themselves could suffice to prevent reacti- 
vation of an established latent infection. 
Why should inhibition of HSV DNA polymerase by PAA 
and inhibition of TK by Ro 31-5140 be synergistic in ner- 
vous tissue? It seems likely that in nervous tissue, where 
deoxynucleoside triphosphate (dNTP) pools are pre- 
sumed to be low, TK would be required to increase such 
pools to allow HSV polymerase function. Although PAA 
inhibits noncompetitively with dNTPs (Mac and Robi- 
shaw, 1975; Eriksson eta/., 1980), in this mode of inhibi- 
tion, decreasing dNTP concentrations does lessen the 
amount of inhibitor required to reduce reaction velocities. 
Similarly, for PKG7, in nervous tissue, a tk mutation that 
decreased dNTP pools might synergize with a mutation 
that raised the Km of polymerase for deoxynucleotide 
triphosphates. Consistent with this idea, the PAAr5 poly- 
merase does exhibit a somewhat elevated Km (St. Clair 
eta/., 1984; Hall et aL, 1985). Whether this is sufficient to 
explain the profound impairment of ganglionic replication 
and reactivatable latent infection observed for PKG7 is 
not certain, 
These considerations lead us to speculate that some 
of the subtler aspects of HSV polymerase (e.g., low Km 
for dNTPs that correlates with drug sensitivity) and TK 
(e.g., high expression levels) might contribute to the abil- 
ity of the virus to replicate in and reactivate from nervous 
tissue. Moreover, these properties might be somewhat 
redundant so that partial abrogation of one would not 
prevent virus replication or reactivation. 
Implications for development of antiviral drugs 
As recently reviewed (Wright, 1994), inhibitors of TK 
have yet to show high potency or complete efficacy in 
either explant or in vivo models of HSV disease (Leib et 
al., 1990; Jacobson et al., 1993; Kaufman et al., 1991; 
Bourne et al., 1992). Some of these problems may relate 
to the requirement for complete inhibition of TK to block 
reactivation, as illustrated by the behavior of mutants 
like KG111 that express low levels of TK yet reactivate. 
Additionally, there is much room for improvement of in- 
hibitors of TK in terms of their pharmacokinetic properties 
(Wright, 1994). Our results suggest that TK inhibitors 
might gain utility in combination with antiviral drugs that 
target polymerase without requiring activation by TK. One 
such inhibitor of polymerase that is already licensed for 
clinical use is foscarnet (phosphoneformic acid), which 
is a congener of PAA. A second class of such inhibitors 
that are under development includes phosphonate deriv- 
atives of nucleosides (De Clercq et al., 1987). Perhaps 
the results showing the synergy of Ro 31-5140 and PAA 
in inhibiting reactivation will merit consideration. 
Additionally, our results suggest that nucleoside ana- 
logs like acyclovir, which are not only substrates for TK 
but also competitively inhibit TK phosphorylation of natu- 
ral substrates, might exert antiviral effects in nervous 
tissue by two mechanisms, (1) inhibition of HSV DNA 
polymerase by phosphorylated forms and (2) inhibition 
of TK. Our results suggest that these two modes of inhibi- 
tion would be synergistic. 
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